La cadena de opciones muestra datos clave de las opciones de acciones de Maravai LifeSciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Maravai LifeSciences..

Maravai LifeSciences (NASDAQ:MRVI) Bolsa, Cadena de Opciones

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Deutsche Bank analyst Brian Bedell reiterates State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Hold and lowers the price target from $104 to $103.

News

Price Target

Reiteration

Analyst Ratings

Deutsche Bank Reiterates Hold on State Street, Lowers Price Target to $103

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) with a Buy and maintains $7 price target.

COCP

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $7 Price Target

Citigroup analyst Asiya Merchant maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $120 to $125.

Citigroup Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $125

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Buy and lowers the price target from $75 to $72.

Deutsche Bank Maintains Buy on H.B. Fuller, Lowers Price Target to $72

Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a Neutral and raises the price target from $142 to $152.

Citigroup Maintains Neutral on 3M, Raises Price Target to $152

Industry partners to provide funding and data to support ACAT&#x2122; model improvements
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT&#x2122;) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

Biotech

General

Simulations Plus And Enabling Technologies Consortium Announce Strategic Collaboration To Advance GastroPlus Enhancements

Global

P&G CFO Says Organic Sales In China Declined 3% In Q2

WIIM

ROKU

Roku shares are trading higher after Netflix reported strong quarterly earnings.

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Neutral.

ATRA

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

United Airlines shares are trading higher after the company reported better-than-expected Q4 financial results.

IBKR

Interactive Brokers shares are trading higher following better-than-expected Q4 financial results.

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and raises the price target from $80 to $85.

SCHW

Citigroup Maintains Neutral on Charles Schwab, Raises Price Target to $85

The Offering is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.&nbsp;

MCTR

CTRL Group Prices $8M Initial Public Offering Of 2M Common Shares At $4/Share

RVSN

Rail Vision shares are trading higher after the company announced a binding MoU with Sujan Ventures to introduce its safety systems to the Indian railway market.

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Deutsche Bank analyst Steve Powers maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $80 to $78.

Deutsche Bank Maintains Hold on Estee Lauder Cos, Lowers Price Target to $78

Financing

IESC

IES Announced That It Has Amended And Restated Its Existing Credit And Security Agreement, Increasing The Commitment Amount Of The Revolving Credit Facility To $300M From $150M And Extending The Maturity Date To January 21, 2030 While Expanding The Size Of The Lending Group

Deutsche Bank analyst Steve Powers maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $184 to $178.

Deutsche Bank Maintains Buy on PepsiCo, Lowers Price Target to $178

Maravai LifeSciences (MRVI) announced that Carl Hull will retire from his position as executive chairman of the board and that the board of directo...

Maravai Lifesciences chairman Carl Hull to retire, R. Andrew Eckert to succeed

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) today. The company's shares clos...

Craig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)

RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on December 8 and set a price ...

RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)

Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is...

Maravai Lifesciences initiated with a Neutral at Guggenheim

Danaher, Cryoport, Sartorius win Buy as Guggenheim expands bioprocessing coverage

Maravai LifeSciences announces prelim unaudited 2024 revenue

The latest announcement is out from Maravai Lifesciences Holdings ( ($MRVI) ). Maravai LifeSciences announced the elimination of the position of An...

Maravai LifeSciences Restructures Leadership Amid Revenue Update

Cconsensus is $260.78M. Maravai said the preliminary year-end results are subject to year-end closing adjustments. Published first on TheFly – the ...

Maravai sees 2024 revenue at midpoint of $255M-$265M range

Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. The company's shares closed last Wednesday at $6.13. Hewitt covers the H...

Craig-Hallum Gives a Buy Rating to Maravai Lifesciences Holdings (MRVI)

ClearBridge Small Cap Strategy Q1 2025 Commentary

ACHC

ALGT

BLMN

CRGY

CYRX

FWRG

GDRX

ICFI

INFR

INSW

KROS

LRGE

MRVI

PCVX

PRIM

RYTM

SARTF

SRRK

TARS

VRNA

XPRO

YETI

YLDE

Earnings

Press Releases

Maravai LifeSciences Reports Second Quarter 2024 Financial Results

Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule

Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

Maravai LifeSciences Reports Third Quarter 2024 Financial Results

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

Maravai LifeSciences Announces November 2024 Investor Conference Schedule

Management

Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

FTRE

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solns

ChromaDex

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Maravai LifeSciences

Maravai LifeSciences (MRVI) Opciones

Maravai LifeSciences (NASDAQ:MRVI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL